LOGIN  |  REGISTER
Cue Biopharma

Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference

March 06, 2024 | Last Trade: US$26.73 0.32 1.21

ATLANTA, March 6, 2024 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate virtually at the upcoming Oppenheimer 34th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 10:40 a.m. ET on March 13, 2023.

A live webcast of the virtual fireside chat will be accessible through Artivion's website, www.artivion.com, on the Investors page. An archived copy of the webcast will be available for 90 days on the same website. 

About Artivion, Inc.

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing simple, elegant solutions that address cardiac and vascular surgeons' most difficult challenges in treating patients with aortic diseases. Artivion's four major groups of products include: aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues. Artivion markets and sells products in more than 100 countries worldwide. For additional information about Artivion, visit our website, www.Artivion.com.

Contacts:

Artivion

Gilmartin Group LLC

Lance A. Berry

Brian Johnston / Laine Morgan

Executive Vice President &

Phone: 332-895-3222

Chief Financial Officer

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Phone: 770-419-3355

 

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB